Licensing deals
![AstraZeneca Invests in Cellectis for Therapy Push](https://pharmtales.com/wp-content/uploads/2023/11/AstraZeneca-Buys-22-of-Cellectis-in-Bold-Cell-Gene-Therapy-Venture.jpg)
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
![Prelude Shifts Focus, Cuts Phase 1 Drugs in New Deal](https://pharmtales.com/wp-content/uploads/2023/11/Prelude-Focuses-on-SMARCA-in-AbCellera-Deal-and-Trims-Its-Portfolio-by-Dropping-Two-Phase-1-Candidates.jpg)
Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates
Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...
![Elektrofi gets $20M from Lilly for drug deal](https://pharmtales.com/wp-content/uploads/2023/10/Elektrofi-lands-20M-from-Eli-Lilly-for-subcutaneous-drug-partnership.jpg)
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
![Merck-Daiichi $22B deal for cancer ADCs](https://pharmtales.com/wp-content/uploads/2023/10/Merck-and-Daiichi-join-forces-to-develop-novel-cancer-drugs-in-22B-deal.jpg)
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
![Basilea acquires antifungal from Eisai](https://pharmtales.com/wp-content/uploads/2023/10/Basilea-buys-clinical-stage-antifungal-from-Eisai-advances-its-anti-infective-strategy.jpg)
Basilea buys clinical-stage antifungal from Eisai, advances its anti-infective strategy
Basilea Pharmaceutica is making a strategic move to bolster its anti-infective pipeline, this time with a $2 million investment in ...
![Roche and Monte Rosa team up for molecular glue](https://pharmtales.com/wp-content/uploads/2023/10/Roche-partners-with-Monte-Rosa-to-develop-molecular-glue-drugs-for-cancer.jpg)
Roche partners with Monte Rosa to develop molecular glue drugs for cancer
In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...
![sotio synaffix deal, sotio adc technology, synaffix adc platform, sotio lead drug halted, sotio news, synaffix news, adc tech licensing,](https://pharmtales.com/wp-content/uploads/2023/10/Sotio-inks-740M-deal-with-Synaffix-for-ADC-technology-after-lead-drug-setback.jpg)
Sotio inks $740M deal with Synaffix for ADC technology after lead drug setback
In a strategic move following the recent setback in its IL-15 asset trials, Sotio Biotech has embarked on an ambitious ...
![Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis](https://pharmtales.com/wp-content/uploads/2023/09/Evommune-abandons-EVO101-a-topical-IRAK4-inhibitor-for-atopic-dermatitis.jpg)
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
![Takeda licenses AcuraStem’s antisense drug for ALS targeting PIKFYVE](https://pharmtales.com/wp-content/uploads/2023/09/Takeda-licenses-AcuraStems-antisense-drug-for-ALS-targeting-PIKFYVE.jpg)
Takeda licenses AcuraStem’s antisense drug for ALS targeting PIKFYVE
As scientific research continues to underscore the potential of targeting the PIKFYVE enzyme in the quest to combat amyotrophic lateral ...
![Septerna Therapeutics, Vertex Pharmaceuticals, Licensing deals, GPCR, GPCR-targeting drugs, Cystic fibrosis](https://pharmtales.com/wp-content/uploads/2023/09/Vertex-partners-with-Septerna-to-develop-GPCR-targeting-drugs-for-rare-diseases.jpg)
Vertex partners with Septerna to develop GPCR-targeting drugs for rare diseases
Septerna, a biotech company, has secured an additional $47.5 million in funding through a licensing agreement with Vertex, a prominent ...